AbCellera Biologics (ABCL) FCF Margin (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly FCF Margin came in at 449.24% in Q1 2026, up 7473.0% YoY from 5.93% in Q1 2025, and down 351.93% on a QoQ basis from 99.4% in Q4 2025.
AbCellera Biologics (ABCL) FCF Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of FCF Margin data on file, last reported at 449.24% in Q1 2026.
- Quarterly FCF Margin rose 7473.0% year-over-year to 449.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 238.91% (up 38101.0% YoY) and the FY2025 annual result came in at 231.69%, up 41670.0% from the prior year.
- FCF Margin slipped to 449.24% in Q1 2026, from 99.4% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 526.37% in Q2 2022 to a low of 728.42% in Q3 2024.
- A 5-year average of 312.02% and a median of 370.87% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 61124 bps — and 2025, when it jumped 41591 bps.
- Tracing ABCL's FCF Margin over 5 years: stood at 86.25% in 2022, then tumbled by 530 bps to 370.87% in 2023, then slipped by 26 bps to 467.92% in 2024, then surged by 79 bps to 99.4% in 2025, then slumped by 352 bps to 449.24% in 2026.
- The last three FCF Margin figures came in at 449.24% (Q1 2026), 99.4% (Q4 2025), and 687.01% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 587.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 587.43% |
| Mar 31, 2026 | -449.24% |
| Dec 31, 2025 | -99.40% |
| Sep 30, 2025 | -687.01% |
| Jun 30, 2025 | -267.91% |
| Mar 31, 2025 | -523.97% |
| Dec 31, 2024 | -467.92% |
| Sep 30, 2024 | -728.42% |
| Jun 30, 2024 | -683.82% |
| Mar 31, 2024 | -661.52% |
| Dec 31, 2023 | -370.87% |
| Sep 30, 2023 | -309.70% |
| Jun 30, 2023 | -72.57% |
| Mar 31, 2023 | -484.31% |
| Dec 31, 2022 | 86.25% |
| Sep 30, 2022 | -137.40% |
| Jun 30, 2022 | 526.37% |
| Mar 31, 2022 | 27.08% |
| Dec 31, 2021 | -18.76% |
| Sep 30, 2021 | -263.36% |